A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer

摘要

The use of stereotactic body radiotherapy (SBRT) for early-stage primary non-small cell lung cancer (NSCLC) reported excellent local control rates. But the optimal SBRT dose for oligometastatic lung tumors (OLTs) from colorectal cancer (CRC) has not yet been determined. This study aimed to evaluate whether SBRT to a dose of 48-60?Gy in 4-5 fractions could result in similar local outcomes for OLTs from CRC as compared to early-stage NSCLC, and to examine potential dose-response relationships for OLTs from CRC. OLTs from CRC and primary NSCLCs treated with SBRT to 48-60?Gy in 4-5 fractions at a single institution were evaluated, and a matched-pair analysis was performed. Local recurrence-free survival (LRFS) was estimated by the Kaplan-Meier method. Univariate Cox regression was performed to identify significant predictors. There were 72 lung lesions in 61 patients (24 OLTs from CRC in 15 patients and 48 NSCLCs in 46 patients) were analyzed with a median follow-up of 30?months. LRFS for OLTs from CRC was significantly worse than that of NSCLC when treated with 48-60?Gy/4-5 fx (p?=?0.006). The 1, 3 and 5-year LRFS of OLTs from CRC vs NSCLC were 80.6% vs. 100%, 68.6% vs. 97.2%, and 68.6% vs. 81.0%, respectively. On univariate analysis, OLTs from CRC treated with higher dose (BED10?=?132?Gy) exhibited significantly better local recurrence-free survival than those treated to lower doses (BED10?≤?105.6?Gy) (p?=?0.0022). The 1 and 3-year LRFS rates for OLTs treated to a higher dose (BED10?=?132?Gy) were 88.9% and 81.5%, vs 33.3%, and not achieved for lower doses (BED10?≤?105.6?Gy). The LRFS of OLTs from CRC after SBRT of 48-60?Gy/4-5 fx was significantly worse than that of primary NSCLC. Lower dose SBRT appeared to have inferior control for OLTs of CRC in this cohort. Further studies with larger sample sizes are needed.